Viracta Therapeutics Days Sales in Receivables 2010-2024 | VIRX

Viracta Therapeutics days sales in receivables from 2010 to 2024. Days sales in receivables can be defined as the average number of days it takes to collect outstanding receiveable amounts from customers.

Viracta Therapeutics Days Sales in Receivables 2010-2024 | VIRX

Viracta Therapeutics days sales in receivables from 2010 to 2024. Days sales in receivables can be defined as the average number of days it takes to collect outstanding receiveable amounts from customers.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$73.4B
Chugai Pharmaceutical (CHGCY)$72.5B
Takeda Pharmaceutical (TAK)$42.2B
Merck (MKKGY)$18.5B
Sandoz Group AG (SDZNY)$17.9B
Astellas Pharma (ALPMY)$17.4B
United Therapeutics (UTHR)$16.1B
Neurocrine Biosciences (NBIX)$14B
Summit Therapeutics (SMMT)$13.5B
Shionogi (SGIOY)$11.9B
Madrigal Pharmaceuticals (MDGL)$6.8B
Orion OYJ (ORINY)$6.2B
Ionis Pharmaceuticals (IONS)$5.5B
Corcept Therapeutics (CORT)$5.2B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.5B
Recursion Pharmaceuticals (RXRX)$2.8B
Dyne Therapeutics (DYN)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.4B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$2.3B
Soleno Therapeutics (SLNO)$2B
Indivior (INDV)$1.7B
Xencor (XNCR)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
Evotec AG (EVO)$1.5B
Ocular Therapeutix (OCUL)$1.4B
Harrow (HROW)$1.3B
Guardian Pharmacy Services (GRDN)$1.3B